Sun Pharma Receives Licensing Agreement For Hair Loss Prevention Drug; Stock At Record High

Sun Pharmaceutical Industries Inc, a subsidiary of India's leading drug manufacturer Sun Pharma, has sealed a licensing agreement with Aclaris Therapeutics Inc for a hair loss prevention drug, according to an official exchange filing.

Under the terms of this licensing agreement, Aclaris has granted Sun Pharma exclusive rights to certain patents, allowing the use of deuruxolitinib-a JAK inhibitor developed by Sun Pharma, or other isotopic forms of ruxolitinib. This agreement targets the treatment of two prevalent hair loss conditions: alopecia areata (AA) and androgenetic alopecia (AGA).

The deal involves an upfront payment of $15 million, along with provisions for regulatory and commercial milestones, along with royalties. Aclaris Therapeutics Inc, a clinical-stage biopharmaceutical company specializing in novel drugs for immuno-inflammatory diseases, is providing Sun Pharma with the exclusive rights.

Deuruxolitinib, recognized as a potential best-in-class JAK inhibitor, became part of Sun Pharma's extensive portfolio following the acquisition of Concert Pharma earlier this year. This strategic move aligns with Sun Pharma's commitment to expanding its therapeutic offerings and addressing significant healthcare challenges.

Alopecia Areata, an autoimmune disease characterized by the immune system attacking hair follicles, leads to partial or complete hair loss on the scalp and body. It affects up to 2.5% of the global population during their lifetime, with limited treatment options currently available. Sun Pharma aims to leverage deuruxolitinib's potential to provide a breakthrough in addressing this condition.

Androgenetic Alopecia, a genetically predetermined disorder linked to an excessive response to androgens, affects up to 50% of males and females. It involves progressive loss of terminal hair on the scalp post-puberty. Sun Pharma's licensing agreement with Aclaris encompasses the use of deuruxolitinib for treating this condition as well, addressing a substantial patient population.

Sun Pharma's recent financial performance has showcased its robust growth trajectory. In the September quarter, the company reported an 11% year-on-year revenue growth. Notably, US generic sales reached $420 million, surpassing estimates of $410 million. Specialty sales stood at $240 million, meeting expectations and contributing to the overall positive outlook.

The market response to Sun Pharma's recent developments has been noteworthy. Despite a slight dip near the flatline on Wednesday, with shares closing at Rs 1,240.35 per share. The stock hit its lifetime high in the previous trading session. Sun Pharma shares have recorded a surge of 25% in the last one year.